TPTX » Topics » Profile of Combined Company

This excerpt taken from the TPTX 8-K filed Jun 12, 2006.

Profile of Combined Company

Strategically focused on CNS diseases and disorders

Complementary pipelines yielding total of 8 product candidates

Two novel product candidates for migraine and chronic pain,  
representing potentially earlier commercialization opportunity

Deep AD pipeline with 6 product candidates to potentially treat broad
continuum of market

Discovery function, funded by collaborations with Eisai

Large market opportunities in migraine, chronic pain and AD

CNS development team with proven track record

Strong balance sheet setting the stage for continued growth and value-

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki